Sars cov 2 rapid antigen testing

A list of personnel involved in the MIA and complete autopsy was created, and they were instructed to self-monitor within 14 days after the procedure. During the three weeks after the autopsy, all the personnel on the list underwent weekly SARS-CoV-2 rapid antigen testing (Roche Diagnostics Deutschland GmbH, Mannheim, Germany). Tests were performed by expert staff using the long nasal swab provided in the antigen test kits as indicated in the user manual.

Two separate lists were created of the personnel participating in MITS and CA procedures, comprising 3 people in the MITS team (1 pathologist and 2 technicians) and 4 in CA team (2 pathologists and 2 technicians). All personnel on the MITS and CA lists underwent weekly SARS-CoV-2 rapid antigen testing (Roche Diagnostics Deutschland) until 3 weeks after the last MITS or CA procedure. Rapid antigen tests were conducted using the nasal swabs included in the test kits and following the instructions in the user manual. Thirty workdays before the study, all the participants underwent SARS-CoV-2 antibody serology testing. Circulating antibodies against SARS-CoV-2 were measured using Elecsys Anti-SARS-CoV-2 assay (Roche Diagnostics International), detecting antibodies against the nucleocapsid antigen.